FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular to a combined pharmaceutical kit comprising a REIC/Dkk-3 gene and an anti-PD-L1 antibody.
EFFECT: invention is effective for treating cancer.
3 cl, 5 dwg, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO HUMAN INTERLEUKIN-2 AND THEIR APPLICATION | 2018 |
|
RU2745451C1 |
| OPTIONS, COMPOSITIONS, AND METHODS FOR USE OF HOMING-ENDONUCLEASE PD-1 | 2017 |
|
RU2781083C2 |
| COMBINATION THERAPY OF ANTIBODY TO PROGASTRIN AND IMMUNOTHERAPY FOR CANCER TREATMENT | 2018 |
|
RU2784604C2 |
| TREATMENT OF DISEASES BY MEANS OF EXPRESSION OF ENZYME WITH DEOXYRIBONUCLEASE (DNase) ACTIVITY IN LIVER | 2019 |
|
RU2773691C2 |
| ANTIBODIES SPECIFIC TO CD47 AND PD-L1 | 2020 |
|
RU2779652C2 |
| VIRUS-LIKE PARTICLES WITH HIGH-DENSITY COATING FOR INDUCTION OF ANTIBODY EXPRESSION | 2017 |
|
RU2813282C2 |
| METHOD OF PREPARING OF RECOMBINANT PLASMID DNA AND A METHOD OF PREPARING OF ZYMOGENIC FORM OF HUMAN PROTEIN C | 0 |
|
SU1838411A3 |
| METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
| FGFR2 INHIBITORS SEPARATELY OR IN COMBINATION WITH IMMUNOSTIMULATING AGENTS IN CANCER TREATMENT | 2016 |
|
RU2745707C2 |
| MOLECULES BINDING WITH CD38 AND PD-L1 | 2017 |
|
RU2764201C2 |
